Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 10,507 |
|
|||||
| News | - | ||||||
| Day High | 1.7973 | Low High |
|||||
| Day Low | 1.7301 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.02 | -1.14% | 1.74 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.76 | 1.7301 | 1.7973 | 1.77 | 1.76 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 115 | 10,507 | US$ 1.75 | US$ 18,437 | - | 1.08 - 26.40 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 16:07:44 | formt | 100 | US$ 1.74 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 5.43M | 3.07M | - | 148k | -18.83M | -6.14 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Sonnet BioTherapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 3/11/2024 | 06:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/14/2024 | 06:35 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/14/2024 | 06:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2/01/2024 | 15:20 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/29/2024 | 15:15 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/04/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 1/02/2024 | 15:19 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 12/27/2023 | 15:56 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/22/2023 | 15:31 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 12/15/2023 | 15:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/14/2023 | 16:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/14/2023 | 16:02 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.77 | 1.89 | 1.66 | 1.78 | 13,836 | -0.03 | -1.69% |
| 1 Month | 1.97 | 2.10 | 1.65 | 1.88 | 21,105 | -0.23 | -11.68% |
| 3 Months | 1.46 | 2.3399 | 1.31 | 1.98 | 109,313 | 0.28 | 19.18% |
| 6 Months | 1.32 | 2.3399 | 1.08 | 1.78 | 83,312 | 0.42 | 31.82% |
| 1 Year | 5.72 | 26.40 | 1.08 | 10.16 | 1,275,567 | -3.98 | -69.58% |
| 3 Years | 656.04 | 840.84 | 1.08 | 151.46 | 2,926,509 | -654.30 | -99.73% |
| 5 Years | 1,915.76 | 4,989.60 | 1.08 | 329.72 | 2,610,668 | -1,914.02 | -99.91% |
Sonnet BioTherapeutics Description
| Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |
